ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "biomarkers and rituximab"

  • Abstract Number: 595 • 2018 ACR/ARHP Annual Meeting

    Predictive VALUE of CD19 SERUM Levels for LONG TERM Therapeutic Response and Utility As Biomarker for Optimization, in Rheumatoid Arthritis Patients Treated with Rituximab

    Sheila Melchor1, Esther Rodriguez-Almaraz2, Jose L. Pablos3 and Patricia Carreira4, 1Rheumatology, Rheumatology Department, Hospital Universitario 12 de Octubre, Spain., Madrid, Spain, 2Hospital Universitario 12 de Octubre, Madrid, Spain, 3Servicio de Reumatología, Rheumatology Department, Hospital 12 de Octubre, Spain, Madrid, Spain, 4Rheumatology Department. Hospital Universitario 12 de Octubre, Madrid, Spain

    Background/Purpose: Rituximab (RTX) is directed against CD20 antigens in B lymphocytes (BL), producing selective depletion of BL, not affecting mature plasmatic cells, without immediate effect…
  • Abstract Number: 560 • 2017 ACR/ARHP Annual Meeting

    Clinical Relevance of Serum Free Light Chain Level As Biomarker in Primary Sjögren′s Syndrome

    Gwenny M. Verstappen1, Johan Bijzet1, Jolien F. van Nimwegen1, Martha S. van Ginkel1, Arjan Vissink2, Hendrika Bootsma1 and Frans G.M. Kroese1, 1Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 2Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: During immunoglobulin synthesis in B-cells, kappa and lambda light chains are produced in excess compared to heavy chains, and the surplus of light chains…
  • Abstract Number: 2118 • 2016 ACR/ARHP Annual Meeting

    Rituximab Treated Non Responder Rheumatoid Arthritis Patients Are Generating a New Autoantibody  Repertoire

    Zoltan Konthur1, Melvin Michael Wiemkes2, Thomas Häupl3, Gerd R. Burmester4 and Karl Skriner5, 1Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, 3Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 4Charité – University Medicine Berlin, Berlin, Germany, 5Humboldt University of Berlin, Berlin, Germany

    Background/Purpose:  Rituximab (RTX) has shown clinical efficacy but up to 40 % of RTX treated rheumatoid arthritis (RA) patients are poor responders (Ann Rheum Dis.…
  • Abstract Number: 3105 • 2016 ACR/ARHP Annual Meeting

    Relationships Between a Serum Biomarker of B Cell Differentiation and B Cell Activating Factor Suggest Possible Distinct Pathways of Response to Rituximab in Patients with Systemic Lupus Erythematosus

    Ricardo Marques1, Laura Heretiu2, David A. Isenberg3, Maria J. Leandro3 and Geraldine Cambridge3, 1Serviço de Medicina Interna B, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, 2Medicine, Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 3Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Rituximab (RTX) has been used off-label in refractory SLE with variable clinical outcomes in different cohorts, with no predictive response markers available. However, the…
  • Abstract Number: 784 • 2013 ACR/ARHP Annual Meeting

    IgG4+ Plasmablasts Are A Novel Biomarker In IgG4-Related Disease

    Mollie Carruthers1, Hamid Mattoo2, Zachary S. Wallace3, Vinay Mahajan4, Shiv Pillai5 and John H. Stone1, 1Rheumatology, Massachusetts General Hospital, Boston, MA, 2Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, 4Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Oncology, Massachusetts General Hospital, Boston, MA

    Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated disorder that responds to B cell depletion with rituximab (RTX). We detected IgG4+ plasmablasts in the sera of…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology